Clinical Trial Update: Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating anlotinib in combination with chemoradiation for locally advanced nasopharyngeal carcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN